A celebrity influencer’s Instagram post for Merz Pharma’s Xeomin (incobotulinumtoxinA) minimized the drug’s serious risks and suggested faster efficacy than demonstrated in clinical trials, the US Food and Drug Administration said.
‘Big Night Out’ Gone Bad: US FDA Says Instagram Post For Merz’s Xeomin Minimizes Risks, Overstates Efficacy
An Office of Prescription Drug Promotion “untitled” letter cites a short-form video by interior designer and TV personality Nate Berkus, continuing an enforcement trend involving drug promotions by social media influencers and celebrities.
